Modality
Gene Therapy
MOA
BCL-2i
Target
IL-23
Pathway
Fibrosis
NASHPTSD
Development Pipeline
Preclinical
Feb 2022
PreclinicalCurrent
NCT06631872
354 pts·NASH
2022-02→TBD·Terminated
354 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
Preclinical
Termina…
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06631872 | Preclinical | NASH | Terminated | 354 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 |